InfraReDx Initiates a Randomized Clinical Trial of LipiScan IVUS Coronary Imaging Guidance to Prevent Heart Attacks During Stenting

InfraReDx announced enrollment of the first patient in its Phase II clinical trial of CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow). CANARY is designed to test the hypothesis that NIR-guided use of an embolic protection device, or filter, during percutaneous coronary intervention can reduce the rate of periprocedural heart attacks in patients identified as having high-risk lipid core plaques.
BusinessWire